Mark Breidenbach
Stock Analyst at Oppenheimer
(1.68)
# 2,996
Out of 4,829 analysts
59
Total ratings
31.15%
Success rate
-0.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $9.50 | +215.79% | 4 | Sep 4, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $14 → $13 | $1.16 | +1,020.69% | 5 | May 21, 2024 | |
| EPIX ESSA Pharma | Reiterates: Outperform | $17 | $1.72 | +888.37% | 5 | Dec 13, 2023 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $6.61 | +1,337.22% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $1.14 | +2,092.98% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $0.78 | +1,182.54% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $240 | $7.06 | +3,301.84% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $3.17 | +4,947.32% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $1.26 | +455.56% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $0.77 | +4,032.77% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $15 | $1.75 | +757.14% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $120 | $1.12 | +10,614.29% | 4 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $1.17 | +836,809.87% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2,700 | $3.50 | +77,042.86% | 3 | Dec 13, 2019 |
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $9.50
Upside: +215.79%
Allogene Therapeutics
May 21, 2024
Maintains: Outperform
Price Target: $14 → $13
Current: $1.16
Upside: +1,020.69%
ESSA Pharma
Dec 13, 2023
Reiterates: Outperform
Price Target: $17
Current: $1.72
Upside: +888.37%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $6.61
Upside: +1,337.22%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $1.14
Upside: +2,092.98%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $0.78
Upside: +1,182.54%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $240
Current: $7.06
Upside: +3,301.84%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $3.17
Upside: +4,947.32%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $1.26
Upside: +455.56%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $0.77
Upside: +4,032.77%
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $1.75
Upside: +757.14%
Oct 18, 2022
Maintains: Outperform
Price Target: $90 → $120
Current: $1.12
Upside: +10,614.29%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $1.17
Upside: +836,809.87%
Dec 13, 2019
Upgrades: Outperform
Price Target: $2,700
Current: $3.50
Upside: +77,042.86%